Discovery Labs Receives Guidance on Respiratory Drug
Posted on: Monday, 22 January 2007, 12:01 CST
Discovery Laboratories has received guidance from the FDA on how it is to achieve the approval of Surfaxin for the prevention of respiratory distress syndrome in premature infants.
The FDA issued an approvable letter regarding the treatment in April 2006, stating that it would approve the drug on receipt of additional information. The advice issued did not include a requirement for additional trials. Instead the FDA requested additional information predominantly involving drug product specifications and related controls.
Discovery anticipates filing its formal response to the approvable letter in September or October 2007, followed by a six-month review cycle by the FDA for potential approval of its new drug application for Surfaxin.
Discovery is planning to initiate the manufacture of new Surfaxin process validation batches this week and will submit six months of related stability data in its forthcoming formal response to the approvable letter. Additionally, the FDA indicated that Surfaxin shelf-life will be determined based upon comparative stability data from historical Surfaxin batches.
"With the clarity gained from the FDA meeting, the top priorities now are completing the necessary work to submit our response to the FDA for Surfaxin approval, and advancing Aerosurf, our aerosolized surfactant therapy, into phase II clinical trials," commented Robert Capetola, president and CEO of Discovery.
Source: Datamonitor
Related Articles
- Discovery Labs Submits Complete Response to May 2008 FDA Approvable Letter for Surfaxin(R) for RDS
- Discovery Labs Provides Guidance On FDA Approvable Letter for Surfaxin for RDS
- FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections
- Merck Receives Non Approvable Letter From FDA for ARCOXIA(R) (Etoricoxib)
- FDA Deems Cephalon Sleep Disorder Drug to Be Approvable
- FDA Lays Out Conditions Before Drug OK
- FDA Issues Approvable Letter in Response to Application for Use of FUZEON With Needle-Free Injection Device
- Forest Laboratories Inc. Says FDA Did Not Approve Its Drug to Treat Mild Alzheimer's
- Colon Cancer Drug Wins Additional Approval
 |
 |
User Comments (0)
RSS Feeds